Pharmacology and Molecular Biology Research Laboratories, f Biological Research Laboratories, n Products Strategy Department I, mExperimental Animal and Toxicological Research Laboratories, Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140, Japan (Received for publication July 14, 1995) Leustroducsin B (LSN-B), a novel colony-stimulating factor (CSF) inducer produced by an actinomycetes, has previously been shown to induce CSF production in bone marrow stromal cells. To determine the biological activity of LSN-Bon hematopoiesis in vivo, LSN-Bwas administered intraperitoneally to mice every day for three to six days. Peripheral platelet counts were markedly elevated on days 4 through to 6 compared with the control mice injected with vehicle. Serum IL-6 levels were low (0.8 ng/ml) or virtually undetectable in the drug treated groups. This cytokine profile suggests that LSN-Binduction of thrombocytosis is mechanistically distinct from other cytokine inducers such as IL-1 or FK-565.
Recently a number of humanhematopoietic growth factors have been genetically cloned and recombinant proteins producedX). Someof them are extremely useful in the treatment of hematopoietic disorders. However, the regulatory mechanismsfor the production or the movementof these factors between cellular compartments remain unclear. Bonemarrowstromal cells may be one of the key elements responsible for the control of hematopoiesis in vivo2\ and therefore, the regulation of CSFproduction by these cells is of interest.
The regulatory mechanism of CSF production in stromal cells was investigated using the clonal stromal cell line KM-1023), to discover three novel CSF inducers named leustroducsin A, B and C4'5). These compounds have a commonstructural motif1* (Fig. 1) and when administered to mice, they augmented host resistance in lethal infection of E. coli6). In this paper, we describe the hematological profiles of mice administrated LSN-Band discuss other related biological activities. In the same discussion, a comparison is made with known cytokine inducers such as IL-17) and .
Materials and Methods

Mice
Seven-week-old specific pathogen-free C57BL/6 male mice, purchased from Japan Charles Rivers, were used for all experiments. Chemicals LSN-B was purified from the culture broth of S. platensis in accordance with a previously reported method^. This preparation was negative (<21 pg/mg) for endotoxin contamination in the Limes lysate assay. For administration, LSN-B was dissolved in ethanol and then diluted to less than 0.5% with saline. The saline containing an equal volume ofethanol was used as vehicle control.
In Vivo Study Design LSN-B was administered intraperitoneally to mice once daily at a dose of either 0.1 or 0.3mg/kg in 0.05ml saline for 6 days. Day 1 was designated as the day after initial injection.
Hematological Examinations
Blood samples were drawn into syringes initially containing EDTA-2Kfrom the abdominal aorta under ether anesthesia. A complete blood count was performed using an automated hematologic analyzer (System-9000, LSN-B was administered intraperitoneally for 6 days. Platelet counts were given as means+S.E. from 6~7 mice at each dose. *P<0.01 vs. vehicle group. Japan Technicon, Japan). Differential counts of white blood cells were performed using an automated blood cell analyzer (Microx HEG-70A, Omron, Japan).
Results
Effect of LSN-Bon Platelet Counts
To assess the biological activity of LSN-Btowards platelet production, 0.1 or 0.3mg/kg of LSN-B was administered intraperitoneally to mice daily for 6 days. As shown in Fig. 2, LSN -B increased platelet counts in a dose-dependent manner. Daily administrations of 0.3 mg/kg of LSN-Binduced significant thrombocytosis on days 4 through to 6 compared with the control mice injected with vehicle. On day 6 at the 0.3mg/kg dosage level, platelet count attained a level of 172% of control mice which equalled or exceeded that observed by IL-6 treatments50. Administrations of 0.1 mg/kg of LSN-B also induced a significant thrombocytosis on days 5 through to 6 and the platelet count level attained was 130% of control mice on day 6. Effect of LSN-B on Other Hematological Parameters Figure 3 shows the effect of LSN-Bin vivo administration on other hematological parameters. Daily administrations of 0.3mg/kg of LSN-B increased total white blood cell counts on days 4 through to 6. The granulocyte population increased by this treatment in turn accounts for most of the increase in total white blood cell counts. Interestingly, administrations of 0.1 mg/kg of LSN-Bdid not change granulocyte counts while platelet counts were changed markedly. LSN-Badministration In a preliminary paper, we reported that LSN-Bhas a strong activity in protecting hosts against infection by E. coli6\ Furthermore it was reported also that serum IL-6 levels were upregulated by treatment with 0.3 mg/kg of LSN-B6). Since IL-6 has a potent thrombopoietic activity in vivo, we expected that LSN-Btreatment would cause thrombocytosis in mice. As shown in Fig. 2, administrations of LSN-Bcaused a marked increase in platelet counts and the increased levels of platelet equalled or exceeded those observed by IL-6 treatments9). inducers like LSN-B, also promote high levels of IL-6 elicitation (28 ng/ml and more than 62.5 ng/ml, respectively) while concomitantly causing thrombocytosis in vivo. Conversely also when IL-6 causes thrombocytosis, it probably requires a high serum concentration of IL-6. From previous work6) LSN-Bwas found to increase serum IL-6 concentrations but the levels of IL-6 were relatively low (about 0.8 ng/ml). Furthermore, administrations of 0. 1 mg/kg of LSN-Bdid not induce detectable amounts of IL-6 (< 15 pg/ml). From this study however, propose to account for the above paradox.
One is the induction of another thrombopoietic cytokine; LIFX1) or oncostatin M12) are the other cytokines which may be mediating the mechanism of thrombocytosis. The other possibility is the site-specific cytokine induction by LSN-B. LSN-B may cause increased levels of thrombopoietic cytokines only in bone marrow which is a major hematopoietic organ. IL-1 is known to induce IL-6 in various cell types other than bone marrow stromal cells. FK-565 is known to stimulate the cytokine production by macrophage in vitro8\ LSN-B has been shown to induce cytokines by bone marrow stromal cells1'2*. Further investigations on tissue-specificities of the above inducers would assist in resolving the paradox.
It is well known that circulating IL-6 causes not only thrombopoiesis but also various adverse effects including fever, chills, weight loss, anemia and elevation of acute phase protein13). Although the precise mechanisms of thrombopoietic activity ofLSN-B is yet to be ascertained, the biological activities elicited by LSN-B seem to be suitable for the treatment of thrombocytopenic disorders. 93 Recently, thrombopoietin was discovered as a physiological factor in normal thrombopoiesis14~18). However the effect of LSN-B on thrombopoietin production remains unknown. Nodoubt because leustroducsins have a novel structure being distinct from that of known inducers1*, their relationship between LSNs and the above thrombopoietic factors will prove to be an interesting area of study. Kohama 
